Sanofi India Limited announces Q2 and H1 2026 unaudited financial results and board updates
Sanofi India · Pharmaceuticals & Biotechnology
Key highlights
- Q2 2026 domestic net sales grew 8%, total net sales grew 6% from Q2 2025; profit before tax rose 19% to ₹112 crore
- Insulin portfolio reported 14% growth, with 58% value and 61% volume market share in basal analogs; public sector business accelerated 70%
- Board approved reconstitution of committees effective October 1, 2026, and noted resignation of Whole Time Director and CFO effective September 30, 2026
Why it's rated notable: the year-on-year change is 20% (20% to 50%)
Original filing
Board Meeting Outcome for Unaudited Financial Results For The Quarter And Half Year Ended 30Th June 2026
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Other financial results filings this fortnight
- Kovai Medical Center Q2 profit ₹7,696.61 lakhs vs ₹5,886.14 lakhs a year earlier
- Siddhika Coatings Limited approves joint venture and announces H1 FY 2026 financials
- Financial resultsBrooks LaboratoriesBrooks Laboratories Limited announces Q2 and H1 FY2026 unaudited financial results
- Financial resultsBrooks LaboratoriesBrooks Laboratories Limited announces Q2 and H1 FY2027 financial results and divestment
- NHC Foods reports Sept 2026 quarter results, 99.98% firm stake, two appointments
- Spectrum Electrical Industries Ltd approves Q2 & H1 results for period ended September 30, 2026
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.